ArticleScientific reports2026
Inhibiting the P2X7R-NLRP3 inflammasome pathway regulates CXCL16 to alleviate podocyte injury in mice with adriamycin nephropathy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Primary nephrotic syndrome (PNS) is a leading cause of chronic kidney disease in children. Focal segmental glomerulosclerosis (FSGS) remains a clinical challenge in terms of treatment. To investigate the role of the P2X7R-NLRP3 inflammasome pathway in podocyte injury in PNS, focusing on its regulation of CXCL16 in FSGS. Clinical renal tissues from children with PNS were analyzed by immunohistochemistry for P2X7R, NLRP3, and CXCL16 expression. In vitro, adriamycin (ADR)-induced podocyte injury models were established, with P2X7R knockdown via lentiviral transduction. Protein and mRNA levels of pathway components and injury markers were assessed by Western Blot and RT-qPCR; IL-1β and IL-18 were measured by ELISA. In vivo, ADR nephropathy was induced with ADR 25 mg/kg by a single tail vein injection in NLRP3-knockout and wild-type male mice (n = 10 per group C57BL/6J, 5 weeks old). Serum albumin, total cholesterol, 24 h urine protein, renal expression of CXCL16, Nephrin, and inflammatory cytokines, and podocyte ultrastructure were evaluated. Glomerular P2X7R, NLRP3, and CXCL16 were significantly upregulated in PNS patients, particularly in FSGS versus MCD. ADR-induced podocytes showed increased expression of these markers and inflammatory cytokines, which P2X7R knockdown reversed. NLRP3 knockout in mice attenuated ADR nephropathy, improving biochemical parameters, reducing proteinuria, downregulating CXCL16 and inflammatory factors, restoring Nephrin, and ameliorating podocyte ultrastructural injury. The P2X7R-NLRP3 inflammasome pathway promotes podocyte injury in PNS via CXCL16 upregulation, revealing novel mechanistic insights and potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.